Validation of the Bowel Function index to detect clinically meaningful changes in opioid-induced constipation

Journal of Medical Economics

Volumn 12, Issue 4, 2009, Pages 371-383

  Rentz, A M ^a   Yu, R ^a   Muller Lissner S ^b   Leyendecker, P ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Park Klinik Weissensee   (Germany)

^c MUNDIPHARMA GMBH   (Germany)

Author keywords

Bowel Function Index; Opioid induced constipation; Pain; Patient reported outcomes

Indexed keywords

LAXATIVE; NALOXONE; OXYCODONE; PLACEBO;

ADULT; ARTICLE; BOWEL FUNCTION INDEX; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTENT VALIDITY; DEFECATION HABIT; DRUG DOSE TITRATION; FECES ANALYSIS; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; INTESTINE FUNCTION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPIOID INDUCED CONSTIPATION; PATIENT PARTICIPATION; REPRODUCIBILITY; SCORING SYSTEM; SUSTAINED DRUG RELEASE; TEST RETEST RELIABILITY; VALIDATION STUDY;

ANALGESICS, OPIOID; CHRONIC DISEASE; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC SELF EVALUATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OXYCODONE; PAIN; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 72749092412     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903430481     Document Type: Article

References (40)

1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5 Suppl):11-18S.
2. Bell T, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10:35-42.
3. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649-671
4. Shahbazian A, Heinemann A, Schmidhammer H, et al. Involvement of μ- and κ-, but not δ-opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea pig intestine. Br J Pharmacol 2002;135:741-750
5. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996;69:103-115
6. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004;16(Suppl 2):17-28.
7. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther 1986;237:945-949
8. Grider JR, Makhlouf GM. Role of opioid neurons in the regulation of intestinal peristalsis. Am J Physiol Gastrointest Liver Physiol 1987;253:G226-31.
9. Wirz S, Wartenberg HC, Wittman M. Post-operative pain therapy with controlled release tramadol following orthopedic surgery: a prospective, randomized, double-blind investigation. Pain Clinic 2005;17:367-376
10. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23:48-53.
11. Avila JG. Pharmacological treatment of constipation in cancer patients. Cancer Control 2004;11(Suppl 1):10-18.
12. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life. The remarkable university of half a standard deviation. Med Care 2003;41:582-592
13. Bates JJ, Foss JF, Murphy DB. Are peripheral opioid antagonists the solution to opioid side effects? Anesth Analg 2004;98:116-122
14. Paulson D, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21 day treatment-randomized clinical trial. J Pain 2005;6:184-192
15. Holzer P. New approaches to the treatment of opioid-induced constipation. Eur Rev Med Pharmacol Sci 2008;12(Suppl 1):119-127
16. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004;361:192-195
17. Meissner W, Leyendecker P, Müller-lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64.
18. Müller-Lissner S, Koch G, Talley NJ, et al. Subjects global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003;56:310-316
19. Draft Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Food and Drug Administration, 2006
20. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-924
21. Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999;34:870-877
22. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006;10:209-217
23. Rome Foundation. Guidelines- Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. J Gastrointestin Liver Dis 2006;15:307-312
24. Nadstawek J, Leyendecker P, Hopp M, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract 2008;62:1159-1167
25. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety for oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-1154
26. Simpson KH, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate to severe noncancer pain. Curr Med Res Opin 2008;24,3503-3512
27. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
28. Hays RD, Anderson RT, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: Staquet MJ, Hays RD, Fayers PM, eds. Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford: Oxford University Press, 1998.
29. Cohen J. Statistical power analyses for the behavioral sciences, 2nd edn. Hillsdale NJ: Lawrence Erlbaum, 1988.
30. Deyo RA, Dieher P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 1991;12:142-58S.
31. Myers JL., Well AD. Research Design and Statistical Analysis, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum, 2003:508.
32. Mc Donald JH. Handbook of Biological Statistics. Baltimore, MD: Sparky House Publishing, 2008. [URL: http://udel.edu/?mcdonald/statanovamodel.html] Accessed April 2009.
33. Hays RD, Revicki DA. Reliability and validity (including responsiveness). In: Fayers P, Hays RD, eds. Assessing Quality of Life in Clinical Trials, 2nd edn. New York: Oxford University Press, 2005.
34. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999;37:469-478
35. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861-873
36. Connell AM, Hilton C, Irwine G, et al. Variation in bowel habits in two population samples. Br Med J 1965;2:1095-1099
37. McMillan SC. Assessing and managing opioid-induced constipation in adults with cancer. Cancer Control 2004;11(Suppl 1):3-9.
38. Müller-Lissner S, Beil W. Moderne Therapie mit Laxanzien. Bremen: UniMed Verlag, 2006.
39. Sweeney MA. Constipation - diagnosis and treatment. Home Care Provid 1997;2:250-255
40. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness or evaluative trials. Br Med J 1998;316:690-693